MINIMED INC (MMED)
Health Care · Diabetes management devices and digital health · NASDAQ
MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management.
What MINIMED INC does
MiniMed develops and markets insulin delivery systems, continuous glucose monitoring (CGM) devices, and smart insulin pen systems for the management of Type 1 and Type 2 diabetes. The company's core product portfolio includes automated insulin delivery (AID) systems like the MiniMed 780G and MiniMed Flex pumps, CGM products such as Guardian Connect, Simplera Sync, and Instinct, and smart multiple daily injection systems including the InPen smart insulin pens. MiniMed operates in over 80 countries and competes across a range of diabetes management technologies serving people with diabetes globally.
Themes: Automated insulin delivery / AID systems, Continuous glucose monitoring (CGM), Type 1 diabetes management, Type 2 diabetes management, Connected diabetes devices, Digital health / mobile diabetes apps
Fundamentals
- Price$20.45 as of 2026-08-21 close
- Market cap$5.7B as of 2026-08-21
- P/En/a negative earnings
- Net margin-10.7% as of 2026-08-24
- Gross margin+54.2% as of 2026-08-24
- ROE-9.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+14.3% FY2026 vs FY2025, SEC XBRL
- Revenue CAGR (3y)+12.1% SEC XBRL
- Beta0.21 as of 2026-08-24
- Last reported earnings2026-06-03 SEC EDGAR Form 8-K (Item 2.02)
How MMED compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MMED is in 2 of our published Top 10 lists.
Short-term Top 10 — since 18 Aug 2026Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
62.7 #105 of 1,704 scored · #28 of 240 in Health Care
Trend 95th: the price is 22% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; setup 74th: day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 90% of it); weakest is catalysts 20th: the analyst consensus rating has softened toward "sell" since the prior reading.
In this list since 18 Aug 2026 — currently 5th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 4, score 71.5.
In this list since 18 Aug 2026 — currently 5th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 1, score 71.5.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How MINIMED INC looks technically
MINIMED INC (MMED): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day high about 8 trading days ago.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.87 | $16.87 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 15.69. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control | 35.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 66.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($18.19 to $20.88) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 84.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.88 | $20.88 |
|---|---|---|
| From the 52-week high | it is 2.1% below its 52-week high (its highest price of the past year) | -2.1% |
| Above the 52-week low | it is 92.0% above its 52-week low (its lowest price of the past year) | +92.0% |
| Below the 52-week high | it is 2.1% below its highest point of the past year | 2.1% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $20.88 (set on 2026-08-13) | $20.88 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 2.1% below its all-time high | -2.1% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $10.65 (set on 2026-05-15) | $10.65 |
| Above the all-time low | it is 92.0% above its all-time low | +92.0% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 90% of it) | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9116 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9116 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.38 and $21.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.38 – $19.22 – $21.07 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.5% since the prior reading | -2.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.21 toward sell |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 14 sessions ago and has not traded back through the level it left behind at 18.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.2% gap up opened on 2026-06-17 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 45 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 20.1 percentage points (the stock gained 22.5% while the market gained 2.3%) | +20.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 71.4 percentage points (the stock gained 74.5% while the market gained 3.1%) | +71.4% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 6 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 6 |
|---|---|---|
| Bearish technical signals | 2 of the 6 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 34% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +33.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid since 2026-03-06, so the typical buyer over that stretch is showing a gain. That average is $15.96 — a volume-weighted average of daily closes over 107 sessions, not a true tick-by-tick VWAP. | +28.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 22% above the average price paid since it last reported on 2026-06-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $16.81 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | +21.6% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $15.69.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $17.79 and $19.42 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently CUT · At the top of its 14-day range (stochastic above 80) · Trading above the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.46 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$20.83 range $15.00 – $25.00; median $20.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MMED
- Consensus EPS estimate$0.09048 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition from established players (Dexcom, Tandem Diabetes Care, Insulet) and emerging competitors in insulin pumps, CGMs, and smart insulin systems, which could erode market share and pricing power","Dependence on reimbursement approval from healthcare insurance providers; regulatory changes in the FDA and other jurisdictions could impact market access and product adoption","Risk of patent expiration on proprietary products leading to generic or reprocessed product competition, and customer delay in purchasing current products if waiting for new product announcements"]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for MMED — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding MMED as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 4,253,714
- Reported value $63,465,413
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MMED had 6,026,212 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MMED had 2.15% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.75 days to cover at the same settlement.
- Reported short interest (shares) 6,026,212
- Short interest (% of shares outstanding) 2.15%
- Prior settlement (shares) 6,345,677
- Reported change -5.03%
- Days to cover (reported) 4.75
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Dexcom, Inc. (DXCM)
- Tandem Diabetes Care, Inc. (TNDM)
- Insulet Corporation (PODD)
- Beta Bionics, Inc.
- Sequel Med Tech, LLC
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MMED vs…
Frequently asked questions
What does MINIMED INC (MMED) do?
MiniMed develops and markets insulin delivery systems, continuous glucose monitoring (CGM) devices, and smart insulin pen systems for the management of Type 1 and Type 2 diabetes. The company's core product portfolio includes automated insulin delivery (AID) systems like the MiniMed 780G and MiniMed Flex pumps, CGM products such as Guardian Connect, Simplera Sync, and Instinct, and smart multiple daily injection systems including the InPen smart insulin pens.
What sector is MINIMED INC (MMED) in?
MINIMED INC (MMED) is classified in the Health Care sector. Its industry is Diabetes management devices and digital health. It trades on NASDAQ.
Who are MINIMED INC's (MMED) competitors?
Notable peers of MINIMED INC (MMED) include Dexcom, Inc., Tandem Diabetes Care, Inc., Insulet Corporation, Beta Bionics, Inc. and Sequel Med Tech, LLC. This peer set is informational only — not financial advice.
Is MINIMED INC (MMED) overbought or oversold right now?
MINIMED INC (MMED) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MMED come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.